ArticleScientific reports2026
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score serves as a predictive indicator for the autogenous arteriovenous fistula maturation failure.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score is an emerging composite indicator that integrates markers of systemic inflammation and nutritional status. This research aims to evaluate the association between the HALP score and the failure of autogenous arteriovenous fistula (AVF) maturation in patients diagnosed with end-stage renal disease (ESRD), as well as to assess its potential predictive utility. A retrospective cohort of 509 ESRD patients who received their first autogenous AVF creation at our institution was enrolled, and their baseline clinical characteristics were compiled. Participants were stratified into two cohorts based on established AVF maturation criteria: a maturation group and a maturation failure group. The HALP score was computed for each patient using the formula: Hemoglobin (g/L) × Albumin (g/L) × Lymphocyte count (/L) / Platelet count (/L). Subsequently, the patient population was divided into four quartiles based on their HALP scores. The relationship between the HALP score and AVF maturation failure was interrogated using both trend analysis and multi-variable adjusted logistic regression models. The analysis revealed that the median HALP score was significantly lower in the maturation failure group compared to the successful maturation group (P < 0.01). When categorized into quartiles (Q1: ≤20.98, Q2: 20.98-32, Q3: 32-49.29, Q4: >49.29), a clear inverse relationship was observed. Using the highest quartile (Q4) as the reference category, patients in the lowest quartile (Q1, HALP ≤ 20.98) demonstrated a substantially elevated risk for AVF maturation failure (Odds Ratio [OR] = 7.34, 95% Confidence Interval [CI] = 3.19-16.89, P < 0.001). In conclusion, among ESRD patients, the HALP score exhibits a significant and independent inverse association with autogenous AVF maturation failure. These findings suggest that the HALP score holds promise as a valuable diagnostic and prognostic tool for estimating the probability of AVF maturation failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.